A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)-Reference-Cited by-同舟云学术

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Published:2019-02-05 Issue:10 Volume:25 Page:2975-2987
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Mayer Ingrid A.,Prat Aleix,Egle Daniel,Blau Sibel,Fidalgo J. Alejandro Pérez,Gnant Michael,Fasching Peter A.,Colleoni Marco,Wolff Antonio C.,Winer Eric P.,Singer Christian F.,Hurvitz Sara,Estévez Laura García,van Dam Peter A.,Kümmel Sherko,Mundhenke Christoph,Holmes Frankie,Babbar Naveen,Charbonnier Laure,Diaz-Padilla Ivan,Vogl Florian D.,Sellami Dalila,Arteaga Carlos L.

Funder

Novartis Pharmaceuticals CorporationNovartis Pharmaceuticals Corporation (NPC)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis;European Journal of Pharmacology;2024-11

2. Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Current Cancer Drug Targets;2024-09

3. Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond;Critical Reviews in Oncology/Hematology;2024-08

4. Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-07-31

5. Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review;Breast Cancer Research;2024-05-22